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Abstract
High-density lipoprotein (HDL) is considered to be an anti-atherogenic lipopro-
tein moiety. Generation of genetically modified (total body and tissue-specific
knockout) mouse models has significantly contributed to our understanding of
HDL function. Here we will review data from knockout mouse studies on the
importance of HDL’s major alipoprotein apoA-I, the ABC transporters A1 and
G1, lecithin:cholesterol acyltransferase, phospholipid transfer protein, and scav-
enger receptor BI for HDL’s metabolism and its protection against atherosclero-
sis in mice. The initial generation and maturation of HDL particles as well as the
selective delivery of its cholesterol to the liver are essential parameters in the life
cycle of HDL. Detrimental atherosclerosis effects observed in response to HDL
deficiency in mice cannot be solely attributed to the low HDL levels per se, as
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the low HDL levels are in most models paralleled by changes in non-HDL-
cholesterol levels. However, the cholesterol efflux function of HDL is of critical
importance to overcome foam cell formation and the development of atheroscle-
rotic lesions in mice. Although HDL is predominantly studied for its
atheroprotective action, the mouse data also suggest an essential role for HDL
as cholesterol donor for steroidogenic tissues, including the adrenals and ovaries.
Furthermore, it appears that a relevant interaction exists between HDL-mediated
cellular cholesterol efflux and the susceptibility to inflammation, which
(1) provides strong support for the novel concept that inflammation and metabo-
lism are intertwining biological processes and (2) identifies the efflux function of
HDL as putative therapeutic target also in other inflammatory diseases than
atherosclerosis.
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1 Introduction
High levels of low-density lipoprotein (LDL) cholesterol are associated with an
increased risk for cardiovascular disease. In contrast, plasma levels of cholesterol
associated with high-density lipoprotein (HDL) are inversely correlated with the
risk of cardiovascular disease (Gordon et al. 1977). Since standard treatment with
statins to lower plasma levels of LDL cholesterol only reduces the risk of cardio-
vascular disease by ~30 % (Cholesterol Treatment Trialists’ (CTT) Collaboration
et al. 2010; Cholesterol Treatment Trialists’ (CTT) Collaborators et al. 2012),
raising plasma levels of HDL cholesterol has been considered a potential additional
therapeutic strategy to overcome disease.
The term HDL refers to a class of alpha-migrating protein/lipid complexes that
differ in size (5–12 nm), shape, and lipidation pattern. In order to be able to
effectively modulate plasma HDL-cholesterol levels, it is of critical importance
to understand the anti-atherogenic potential and metabolism of the different HDL
particles. Due to the large biological/genetic variation and lifestyle of people, it is
difficult to gain clear insight into the relation between the flux of cholesterol
through the HDL pathway and the development of atherosclerosis—the primary
underlying cause of cardiovascular disease—in the general human population.
Small animal models, in particular mice, have been proven valuable tools to
increase the understanding of the complexity of HDL metabolism and the
consequences of interfering in specific pathways or atherosclerosis susceptibility.
Here we will review data from several genetically modified (total body and tissue-
specific knockout) mouse models to (1) show the importance of specific gene
products in the life cycle of HDL and their contribution to HDL’s primary function,
reverse cholesterol transport, i.e., the flux of cholesterol from peripheral cells back
to the liver for subsequent excretion, and (2) highlight the potential of modulation
of HDL metabolism as an approach to lower atherosclerotic disease burden.
2 Apolipoprotein A-I
Apolipoprotein A-I (apoA-I) is produced by the liver (Zannis et al. 1983) and
intestine (Gordon et al. 1982) and represents the primary apolipoprotein constituent
of HDL particles (Scanu et al. 1969). Several mutations in the apoA-I gene have
been causally linked to HDL deficiency in humans (Tilly-Kiesi et al. 1995; Leren
et al. 1997; Matsunaga et al. 1999; Hovingh et al. 2004; Dastani et al. 2006; Wada
et al. 2009; Berge and Leren 2010; Lee et al. 2013).
The groups of Nobuyo Maeda (Williamson et al. 1992) and Jan Breslow (Plump
et al. 1997) both inactivated the apoA-I gene in mice using dedicated homologous
recombination strategies, leading to the absence of detectable amounts of apoA-I
protein in plasma. In accordance with an important function for apoA-I in the
formation and stability of HDL particles, genetic disruption of apoA-I in mice is
associated with an 83 % decrease in the level of HDL cholesterol, contributing to a
68 % decrease in plasma total cholesterol levels (Williamson et al. 1992). The
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limited amount of HDL cholesterol present in apoA-I knockout mice is carried by
particles that are enriched in triglycerides (Plump et al. 1997). However, HDL
particle size and shape are similar to that of wild-type controls. ApoA-I-deficient
HDL particles display increased levels of other apolipoprotein subspecies, includ-
ing apolipoprotein A-II (apoA-II), apolipoprotein E (apoE), and apolipoprotein
A-IV (apoA-IV) (Li et al. 1993; Plump et al. 1997; Moore et al. 2003). Homozy-
gous apoA-I deficiency in mice not only lowers plasma levels of HDL cholesterol,
but also decreases levels of cholesterol associated with apoB-containing very-low-
density lipoproteins (VLDL) (Plump et al. 1997). The cholesterol ester to
unesterified cholesterol ratio is lower in plasma of apoA-I-deficient mice, which
can be attributed to a reduced endogenous cholesterol esterification rate (Parks
et al. 1995). Furthermore, the cholesterol ester fatty acid composition of plasma is
markedly different between the different genotypes, with apoA-I knockout mice
displaying a higher degree of fatty acid saturation as compared to wild-type mice
(Parks et al. 1995). ApoA-I, in addition to its structural role, thus also serves as an
essential activator of the enzyme lecithin-cholesterol acyltransferase (LCAT) that
esterifies cholesterol.
ApoA-I deficiency in mice does, in general, not affect tissue cholesterol levels
(Plump et al. 1997). In the liver, decreased delivery of cholesterol esters to
hepatocytes is compensated by a concomitant decrease in bile acid formation as
judged from a decrease in hepatic mRNA expression levels of cholesterol 7alpha-
hydroxylase (CYP7A1) in apoA-I knockout mice (Plump et al. 1997). In contrast,
the adrenals are not able to cope with the diminished plasma cholesterol flux due to
the lack of apoA-I. Cortical cells located in the zona glomerulosa and zona
fasciculata from the adrenals of wild-type mice are filled with large lipid droplets
containing cholesterol esters, while adrenals from apoA-I-deficient mice
completely lack cholesterol esters and display a parallel decrease in microvillar
channel width (Plump et al. 1996). Importantly, apoA-I-deficient mice show a
diminished adrenal glucocorticoid output in response to steroidogenic triggers
(Plump et al. 1996), suggesting that a lack of apoA-I-containing HDL particles
impairs normal adrenal function in mice. Although the cholesterol ester content of
the testis is similar between apoA-I knockout and wild-type mice, interstitial and
theca cells within the ovaries of apoA-I knockout mice are similarly deprived of
cholesterol esters (Plump et al. 1996). Currently no evidence is present for an
altered female fertility, despite the clear ovarian cholesterol depletion phenotype.
Combined, these findings indicate that apoA-I-containing HDL particles act as
important cholesterol donors for several, but not all, steroidogenic tissues.
Human apoA-I mutation carriers may develop premature atherosclerosis
(Hovingh et al. 2004; Dastani et al. 2006). The formation of atherosclerotic lesions
in normolipidemic mice can be induced by feeding them a cholic acid-containing
diet enriched in cholesterol and fat that increases levels of pro-atherogenic apoB-
containing lipoproteins (Paigen et al. 1987; Ishida et al. 1991). Strikingly, deletion
of apoA-I in wild-type mice does not alter the incidence or extent of atherogenic
diet-induced lesion formation (Li et al. 1993). This may be explained by the fact
that, under cholic acid-containing diet feeding conditions, levels of anti-atherogenic
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HDL as well as levels of pro-atherogenic VLDL/LDL are lower in apoA-I knockout
mice as compared to wild-type controls (Li et al. 1993). To further determine the
impact of apoA-I deficiency on atherosclerosis susceptibility, apoA-I knockout
mice have been crossbred with genetically hyperlipidemic low-density lipoprotein
receptor (LDLr) knockout mice that spontaneously develop atherosclerotic lesions
on a chow diet, albeit at a slow rate (Ishibashi et al. 1994). Chow diet-fed apoA-I x
LDLr double knockout (DKO) mice as compared to LDLr single knockout controls
exhibit an increase in the plasma non-HDL-cholesterol to HDL-cholesterol ratio.
This can be attributed to a marked increase in VLDL-cholesterol levels and a
decrease in plasma HDL-cholesterol levels (Moore et al. 2003; Zabalawi
et al. 2003). In accordance with the more atherogenic lipoprotein profile (higher
VLDL cholesterol and lower HDL cholesterol), atherosclerotic lesion burden is
increased in chow diet-fed apoA-I x LDLr DKO mice, as measured by en face
analysis of the aorta, irrespective of the age of the mice (Moore et al. 2003).
Feeding a Western-type high fat/high cholesterol diet induces a rapid progression
of atherosclerotic lesion development in LDLr knockout mice (Ishibashi
et al. 1994). In great contrast with the chow diet findings, the extent of atheroscle-
rotic lesion formation was not significantly different between LDLr KO and apoA-I
x LDLr DKO mice upon feeding an atherogenic diet containing 10 % saturated fat
from palm oil and 0.1 % cholesterol for 16 weeks (Zabalawi et al. 2003). However,
it should be noted that apoA-I x LDLr DKO mice show a much lower diet-induced
increase in VLDL-cholesterol levels. Identical aortic cholesterol contents are thus
found in the context of a ~70 % lower plasma total cholesterol level (Zabalawi
et al. 2003). It therefore appears that ablation of apoA-I function and the concomi-
tant decrease in plasma HDL-cholesterol levels do predispose for atherosclerotic
lesion development in mice, but only after correcting for apoA-I genotype-
associated changes in VLDL-cholesterol levels.
ApoA-I x LDLr DKO mice develop severe (fatal) skin lesions containing lipid-
filled macrophages upon feeding the high cholesterol/high fat diet (Zabalawi
et al. 2003). In addition, B-cells, T-cells, and dendritic cells within lymph nodes
of apoA-I x LDLr DKO mice are enriched in cholesterol esters (Wilhelm
et al. 2009). This is associated with an autoimmune phenotype characterized by
relatively high autoantibody titers in plasma upon feeding an atherogenic high
fat/high cholesterol diet (Wilhelm et al. 2009). ApoA-I-containing HDL particles
thus also play an essential role in maintaining cholesterol homeostasis in the skin as
well as in cells from the lymphoid system.
3 ATP-Binding Cassette Transporter A1
The cholesterol used to transform pre-beta1HDL into discoidal alpha-migrating
HDL particles can be supplied through passive diffusion driven by a concentration
gradient. However, it has become clear that energy-dependent flux of cholesterol
and phospholipid across the membrane facilitated by members of the ATP-binding
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cassette (ABC) family of transporters contributes significantly to the lipidation of
apoA-I.
Human carriers of a mutation in the full size ABC transporter ABCA1 gene
suffer from familial HDL deficiency (Brooks-Wilson et al. 1999; Bodzioch
et al. 1999; Hong et al. 2002). In accordance with a prominent role for ABCA1 in
the control of HDL biogenesis, total body ABCA1-deficient mice are characterized
by an almost complete lack of HDL cholesterol (>90 % decrease) in the context of
similar levels of triglyceride-rich lipoproteins (Christiansen-Weber et al. 2000;
Orso´ et al. 2000; Calpe-Berdiel et al. 2005; Brunham et al. 2006). Mature alpha-
migrating HDL particles are virtually absent in ABCA1 knockout mice. The
remaining HDL cholesterol is carried by pre-beta HDL particles that are relatively
enriched in triglycerides and exhibit an altered phospholipid species distribution
(Orso´ et al. 2000; Francone et al. 2003). ABCA1 knockout mice display a dimin-
ished LCAT activity (Francone et al. 2003), which highlights that lipidation of
apoA-I via ABCA1 is required for LCAT activity and maturation of HDL.
Adrenocortical cells (Orso´ et al. 2000) and testical Sertoli cells (Christiansen-
Weber et al. 2000) of mice lacking ABCA1 show distinct accumulation of choles-
terol esters. This can possibly be attributed to the observed increase in the activity
of the cholesterol synthesis gene HMG-CoA reductase (Drobnik et al. 2001). How-
ever, ABCA1 may also act as a local regulator of steroidogenic tissue cholesterol
homeostasis. In further support of a crucial role of ABCA1 in the control of normal
steroidogenesis and development, pregnant ABCA1-deficient females exhibit
lower plasma progesterone and estrogen levels (Christiansen-Weber et al. 2000).
Furthermore, placentas of ABCA1 knockout mice often show malformations,
which translates into a diminished birth and survival rate of ABCA1 knockout
pups (Christiansen-Weber et al. 2000).
Livers and intestines of ABCA1 knockout mice are depleted of cholesterol esters
(Orso´ et al. 2000). Within the liver of wild-type mice, relatively high mRNA and
protein expression levels of ABCA1 are found in hepatocytes and tissue
macrophages (Kupffer cells) (Lawn et al. 2001; Hoekstra et al. 2003), while in
the intestine ABCA1 expression seems to be mostly restricted to macrophages in
the lamina propria of villi (Lawn et al. 2001). Dedicated gene targeting strategies
have been employed to delineate the contribution of the different cell compartments
to plasma HDL-cholesterol levels and total body cholesterol homeostasis. Condi-
tional disruption of ABCA1 function specifically in parenchymal liver cells with
the use of the Cre/Flox gene targeting system impairs the apoA-I-mediated efflux of
cholesterol and phospholipid from hepatocytes without altering the efflux of cho-
lesterol from macrophages to apoA-I (Timmins et al. 2005). Plasma
HDL-cholesterol levels are ~80 % lower as a result of liver-specific ABCA1
deficiency (Timmins et al. 2005). Liver-specific deletion of ABCA1 is also
associated with hypercatabolism of apoA-I by the kidneys resulting in an increased
turnover of HDL particles and a marked decrease in steady-state plasma apoA-I
levels (Timmins et al. 2005; Singaraja et al. 2006). Although no data on the effect of
general ABCA1 deficiency in mice on apoA-I flux have been described, it can be
assumed total body ABCA1 knockout mice similarly show an increased catabolism
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and clearance of apoA-I by the kidneys. ABCA1 deficiency in hepatocytes is
associated with a rise in plasma levels and size of triglyceride-rich VLDL particles,
which can be attributed to an increase in hepatic VLDL secretion and a parallel
decrease in lipoprotein lipase (LPL)-mediated catabolism of triglycerides (Sahoo
et al. 2004; Chung et al. 2010). ABCA1-mediated transport of cholesterol from
hepatocytes to the plasma compartment thus not only controls HDL biogenesis, but
also impacts on the synthesis and catabolism of non-HDL particles. Deletion of
ABCA1 specifically in intestinal epithelial cells is associated with an accumulation
of cholesterol esters in the intestine, a lower plasma apoA-I concentration, and a
~30 % decrease in plasma HDL-cholesterol levels (Brunham et al. 2006). In
contrast to total body and hepatocyte-specific knockout mice, intestinal-specific
ABCA1 knockout mice do not show major changes in non-HDL-cholesterol and
plasma triglyceride levels (Brunham et al. 2006), which further highlights the role
of hepatocyte ABCA1 in the control of plasma triglyceride levels. Importantly,
mice genetically lacking ABCA1 in both the liver and intestine show a greater
decrease in plasma HDL-cholesterol levels as compared to their single tissue
knockout controls, almost reaching similarly low levels as those found in total
body ABCA1 knockout mice (Brunham et al. 2006). Hepatocytes and the intestinal
epithelium can thus be considered the primary cellular sources of the cholesterol
that is used for lipidation of apoA-I and generation of HDL.
Loss-of-function mutations in the ABCA1 gene could not be associated with
increased coronary heart disease in the general population (Frikke-Schmidt
et al. 2008a). However, several studies have suggested that premature atheroscle-
rosis and cardiovascular disease are a common finding in human carriers of
functional mutations in the ABCA1 gene (Huang et al. 2001; Hong et al. 2002;
Frikke-Schmidt et al. 2008b). In contrast, total body ABCA1 deficiency does not
alter the susceptibility to atherosclerosis in hyperlipidemic apoE knockout and LDL
receptor (LDLr) knockout mice fed either regular chow or an atherogenic high
fat/high cholesterol diet (Aiello et al. 2002). However, deletion of ABCA1 function
in the context of genetic hyperlipidemia is not only associated with HDL deficiency
but also with a significant decrease in the plasma concentration of cholesterol
carried by pro-atherogenic VLDL/LDL (Aiello et al. 2002). As is also the case
for apoA-I, normal ABCA1 function in mice thus only protects against atheroscle-
rosis after correcting for ABCA1 genotype-associated confounding differences in
atherogenic lipoprotein levels. The atheroprotective effect of ABCA1 may be
attributed to its general impact on plasma HDL-cholesterol levels or specifically
due to its potential role in the efflux of cholesterol from macrophages. Lipid-filled
foam cells can be found in all macrophage-rich tissues of hyperlipidemic total body
ABCA1 knockout mice (Aiello et al. 2002), which already hints to an important
in vivo role for ABCA1 in macrophage cholesterol efflux. The capacity of ABCA1
knockout mice to facilitate reverse cholesterol transport, the transport from periph-
eral cells—i.e., macrophages—back to the liver for subsequent excretion, has been
validated by measuring the recovery in the plasma compartment and feces of
radiolabeled cholesterol from intraperitoneal administered macrophages. In line
with the hypothesis that ABCA1-mediated cholesterol efflux is an important
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determinant of reverse cholesterol transport, a lower amount of radiolabeled cho-
lesterol is excreted under the condition of both total body and macrophage-specific
ABCA1 deficiency (Calpe-Berdiel et al. 2005; Wang et al. 2007).
Aiello et al. (2002) and Van Eck et al. (2002) utilized bone marrow transplanta-
tion to explore the specific effect of ABCA1-dependent macrophage cholesterol
efflux on atherosclerosis susceptibility. In accordance with a negligible impact of
macrophage ABCA1 on total HDL biogenesis, bone marrow ABCA1 deficiency
does not alter plasma HDL-cholesterol levels (Haghpassand et al. 2001; Aiello
et al. 2002; Van Eck et al. 2002). Atherosclerotic lesion development in apoE
knockout mice is markedly enhanced—at multiple sites—in response to disruption
of ABCA1 expression in bone marrow (Aiello et al. 2002). Transplantation of
ABCA1 knockout bone marrow into lethally irradiated LDLr knockout mice
similarly stimulates atherosclerotic lesion development (Van Eck et al. 2002).
ABCA1-mediated efflux of cholesterol from leukocytes is thus an important pro-
tective mechanism to inhibit macrophage foam cell formation and atherosclerosis
in mice. Remarkably, macrophage-specific ABCA1 deficiency does not affect the
extent of atherosclerosis in LDLr knockout mice (Brunham et al. 2009). It can
therefore be concluded that ABCA1’s function in macrophages does not confer
protection against atherosclerosis, but that rather an efficient efflux of cholesterol
from lymphocytes or other immune cells is essential to overcome disease.
Relative HDL deficiency in liver-specific ABCA1 knockout mice on a
hyperlipidemic LDLr knockout background is not associated with any enhanced
susceptibility for the initial development of macrophage-rich atherosclerotic
lesions, while the development of more advanced (collagen-containing) plaques
is inhibited (Bi et al. 2013). In accordance with a prominent role for macrophage
ABCA1 in reverse cholesterol transport, no change is observed in the flux of
cholesterol from macrophages to the feces in LDLr knockout mice lacking
ABCA1 function only in hepatocytes (Bi et al. 2013). Strikingly, apoE knockout
mice that contain hepatocyte-specific ABCA1 deficiency do show an increased
susceptibility to atherosclerosis, despite lowered plasma VLDL/LDL-cholesterol
levels (Brunham et al. 2009). A critical review of these data has suggested that the
discrepancy in the atherosclerosis findings from liver-specific ABCA1 knockout
mice may be attributed to differences in inflammatory status of the two
hyperlipidemic mouse models (Van Eck and Van Berkel 2013), which makes
proper interpretation of the findings difficult. However, due to the inconsistency
of the aforementioned results, it seems clear that the decrease in plasma
HDL-cholesterol levels due to deletion of ABCA1 function should not be consid-
ered the driving force for the increase in atherosclerosis in total body ABCA1
knockout mice.
A consistent decrease in plasma VLDL-cholesterol levels is observed in LDLr
knockout mice that have been transplanted with ABCA1-deficient bone marrow
upon feeding an atherogenic Western-type diet (Van Eck et al. 2002; Lammers
et al. 2011, 2012). This finding suggests that modulation of the leukocyte choles-
terol efflux rate can directly impact on the metabolism of VLDL particles in vivo.
However, to date, the mechanism underlying this effect remains to be resolved. It is
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becoming more and more evident that immunology and metabolism are not just two
separate disciplines, but that they intervene and impact each other at multiple levels
(Mathis and Shoelson 2011). ABCA1-deficient macrophages display a higher
sensitivity to the bacterial membrane component lipopolysaccharide (LPS) (Zhu
et al. 2008; Yvan-Charvet et al. 2008) and myeloid cell-specific ABCA1 knockout
mice are protected against bacterial infection (Zhu et al. 2012). Furthermore,
ABCA1 deficiency in bone marrow is associated with an increase in blood leuko-
cyte counts (Van Eck et al. 2002). Given the apparent link between ABCA1 and
immune function in vivo, future research should be aimed at uncovering to what
extent ABCA1 contributes to the interplay between inflammation and cholesterol
metabolism.
4 ATP-Binding Cassette Transporter G1
ABCG1, formerly known as the ABC8/white gene, belongs to the family of ABC
half transporters that need to dimerize to execute their function. ABCG1 expression
is mostly restricted to macrophage-rich tissues, including liver, spleen, and lung
(Klucken et al. 2000), where it acts as an intracellular sterol transporter (Tarling and
Edwards 2011). ABCG1 mRNA expression can actually be used as a measure for
the hepatic macrophage content in rodent livers, despite detectable levels of
ABCG1 expression in hepatocytes (Hoekstra et al. 2003; Ye et al. 2008; Li
et al. 2012). The capacity to efflux cholesterol to HDL is diminished in ABCG1-
deficient macrophages, while the apoA-I-mediated cholesterol efflux rate is similar
as compared to wild-type macrophages (Out et al. 2006). ABCG1 and ABCA1 thus
interact with different HDL subspecies (mature HDL vs. pre-beta HDL) to facilitate
their cholesterol efflux function. To date, no association between ABCG1
mutations and HDL-cholesterol levels has been described in humans, suggesting
that ABCG1 does not significantly contribute to HDL biogenesis. In accordance,
under basal chow diet feeding conditions, ABCG1 knockout mice do not exhibit a
change in plasma total or HDL-cholesterol levels (Out et al. 2007; Wiersma
et al. 2009).
Chow-fed ABCG1-deficient mice exhibit a severe pulmonary lipidosis pheno-
type, starting from the age of ~6 months, which is characterized by accumulation of
phospholipids, cholesterol crystals, and inflammatory infiltrates in sub-pleural areas
of the lung (Balda´n et al. 2006a, 2008; Wojcik et al. 2008). The distinct lung
phenotype in total body ABCG1 knockout mice can be specifically attributed to the
lack of ABCG1 in bone marrow-derived cells, presumably macrophages. Lethally
irradiated normolipidemic mice transplanted with ABCG1-deficient bone marrow
also show inflammatory cell infiltrates in their lungs, while normalization of
macrophage ABCG1 function prevents the occurrence of pulmonary lipidosis in
total body ABCG1 knockout mice (Wojcik et al. 2008). Alveolar macrophages
from ABCG1 knockout mice have a foamy appearance and display compensatory
upregulation of the cholesterol efflux gene ABCA1 (Balda´n et al. 2006a). In vitro
cultured macrophages lacking ABCG1 are more susceptible to surfactant-induced
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cholesterol accumulation (Balda´n et al. 2006a). ABCG1-mediated cholesterol
efflux to HDL is thus essential for the protection against specifically surfactant-
induced foam cell formation under normolipidemic conditions, since no accumula-
tion of lipid has been noted in other macrophage-rich tissues in chow-fed ABCG1-
deficient mice (Out et al. 2008a). The pulmonary lipidosis phenotype is exacerbated
upon challenging the mice with a cholic acid-containing atherogenic diet (Out
et al. 2007). Under atherogenic diet feeding conditions, ABCG1 knockout mice
also show marked lipid accumulation in cells within and surrounding the germinal
centers of the spleen (Out et al. 2007). This finding highlights that ABCG1 is not
solely involved in maintaining cholesterol homeostasis locally within the lungs.
Variations in the human ABCG1 gene have been linked to an altered risk for
atherosclerotic disease that cannot be explained by changes in lipoprotein levels
(Furuyama et al. 2009). In accordance with a role for murine ABCG1 in the
protection against atherosclerosis, a higher extent of lesion formation, in the context
of similar plasma lipoprotein levels, is detected in ABCG1 knockout mice as
compared to wild-type littermate controls upon feeding atherogenic diet (Out
et al. 2007). The bone marrow transplantation technique has been applied to
elucidate the specific contribution of macrophages in the atheroprotective effect
of ABCG1. In line with the prominent role of macrophage ABCG1 in the preven-
tion of pulmonary lipidosis, extensive lipid accumulation is observed also in lungs
of hyperlipidemic mice transplanted with ABCG1 knockout bone marrow (Out
et al. 2006; Balda´n et al. 2006b). However, contrasting effects on atherosclerosis
outcome have been noted upon bone marrow-specific ABCG1 deletion. Macro-
phage ABCG1 appears to protect against atherosclerosis in LDLr knockout mice as
evident from the initial studies by Out et al. (2006). In marked contrast, similar
studies by Balda´n et al. in LDLr and apoE knockout mice (Balda´n et al. 2006b) and
Ranalletta et al. in LDLr-deficient mice (Ranalletta et al. 2006) have identified
macrophage ABCG1 as being a pro-atherogenic factor. Importantly, following
critical review of all the present data and additional bone marrow transplantation
studies, Meurs et al. have been able to clarify the evident discrepancy in the findings
regarding the role of macrophage ABCG1 in atherosclerosis. The effect of disrup-
tion of ABCG1 function in macrophages on atherogenesis appears to be highly
dependent on the stage of lesion development (Meurs et al. 2012). Diminished
ABCG1-mediated efflux of cholesterol to HDL stimulates the formation of foam
cells and accelerates lesion development in initial plaques that primarily contain
macrophages. During later stages of the disease, macrophage ABCG1 deficiency
inhibits plaque progression as a result of activation of compensatory
atheroprotective mechanisms, i.e., hypersecretion of apoE from macrophages
(Ranalletta et al. 2006), and/or an increased apoptosis rate of lipid-laden macro-
phage foam cells (Balda´n et al. 2006b).
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5 Lecithin-Cholesterol Acyltransferase
Discoidal small HDL particles are able to carry a relatively limited load of choles-
terol. In order for nascent HDL species to become fully enriched in cholesterol, the
unesterified cholesterol acquired upon cellular efflux has to be esterified for
subsequent storage in the core of more mature spherical HDL particles. The
hepatocyte-derived enzyme lecithin-cholesterol acyltransferase (LCAT) is consid-
ered to be the sole mediator of cholesterol esterification in HDL in humans, since
familial LCAT deficiency is characterized by a >95 % decrease in plasma
HDL-cholesterol ester levels (Glomset et al. 1970). As such, homozygous carriers
of loss-of-function mutations in LCAT present with HDL deficiency, while half of
normal HDL-cholesterol values are observed in heterozygous carriers
(Santamarina-Fojo et al. 2000; Hovingh et al. 2005). Two different strains of
LCAT knockout mice have been generated through genetic deletion of respectively
exon 1 or exons 2–5. In accordance with a major role for LCAT in the maturation of
HDL, both types of LCAT-deficient mice show severe HDL-cholesterol deficiency
(>90 % decreased; Ng et al. 1997; Sakai et al. 1997). This coincides with a
significant decrease in plasma apoA-I levels (Ng et al. 1997), probably as a result
of apoA-I hypercatabolism by the kidneys. The remaining plasma HDL cholesterol
in LCAT knockout mice is contained in its unesterified form (Ng et al. 1997; Sakai
et al. 1997).
Besides the clear HDL deficiency phenotype, LCAT knockout mice display
significant changes in the metabolism of triglyceride-rich lipoproteins. Homozy-
gous LCAT-deficient mice show hypertriglyceridemia and an increase in plasma
VLDL-cholesterol levels on a chow diet (Sakai et al. 1997; Lambert et al. 2001; Ng
et al. 2002). This phenotype is preserved when mice are fed a Western-type diet
enriched in fat (Li et al. 2007). Furthermore, extensive triglyceride deposition can
be observed within livers of LCAT knockout mice upon Western-type diet feeding
(Li et al. 2007). Mechanistic studies in LCAT x LDLr double knockout mice have
indicated that the hypertriglyceridemia can be attributed to an increase in secretion
of triglyceride-rich VLDL particles and a decrease in the LPL-mediated lipolysis
rate (Ng et al. 2004). As evidenced by lower fasting glucose and insulin levels,
LCAT knockout mice exhibit an improved glucose tolerance and insulin sensitivity
when crossbred onto the hyperlipidemic LDLr knockout background
(Ng et al. 2004; Li et al. 2007). LCAT-mediated cholesterol ester formation thus
not only contributes to the formation of mature HDL particles, but also (indirectly)
impacts on fatty acid and glucose metabolism.
A genetic defect in LCAT does, in general, not affect the tissue cholesterol
balance in mice (Ng et al. 1997). However, adrenals of LCAT knockout mice show
gross morphological changes associated with neutral lipid depletion, i.e., they have
a more red/brownish color instead of the normal white appearance after perfusion
(Ng et al. 1997). Specifically adrenocortical cells within the zona fasciculata, but
not zona glomerulosa, are deprived from neutral lipid stores (Hoekstra et al. 2013a).
This results in an overall ~80 % decrease in adrenal cholesterol ester content
(Ng et al. 1997). Probably as a compensatory response to overcome cholesterol
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insufficiency, marked increases in the expression of genes involved in the de novo
synthesis and extracellular acquisition of cholesterol can be detected in LCAT
knockout adrenals (Ng et al. 1997). Importantly, in support of the notion that
HDL act as cholesterol donors for the synthesis of glucocorticoids by the adrenals,
LCAT knockout mice display a 40–50 % reduction in the maximal glucocorticoid
output (Hoekstra et al. 2013a). A minor decrease in tissue cholesterol content is also
noted in ovaries, but not testis, in response to LCAT deficiency in mice (Tomimoto
et al. 2001), which does not translate into apparent changes in female fertility.
LCAT knockout mice on a normolipidemic background are virtually protected
against cholic acid containing diet-induced formation of atherosclerotic lesions
(Lambert et al. 2001). Chow diet-fed LCAT x apoE double knockout mice also
display a decrease in atherosclerotic lesion formation, as compared with apoE
single knockout controls (Lambert et al. 2001; Ng et al. 2002). Ablation of LCAT
function is associated with marked HDL deficiency under all hyperlipidemic
conditions. Strikingly, mixed results on the effect of LCAT deficiency on athero-
sclerosis susceptibility, however, have been noted in hyperlipidemic mice upon
feeding diets enriched in fat. LCAT x LDLr double knockout mice display a lower
atherosclerotic lesion burden upon feeding a cholic acid-containing diet (Lambert
et al. 2001). In contrast, LCAT deficiency stimulates the formation of atheroscle-
rotic lesions feeding in LDLr knockout mice upon feeding a Western-type diet
devoid of cholic acid, as judged by the aortic cholesterol content (Furbee
et al. 2002; Lee et al. 2004). Furthermore, LCAT x apoE double knockout mice
also exhibit an increase in their aortic cholesterol content upon feeding the
Western-type high fat diet (Furbee et al. 2002). Importantly, lower plasma levels
of non-HDL cholesterol are found in the hyperlipidemic LCAT knockout mice
under cholic acid-containing diet feeding conditions (Lambert et al. 2001), while
non-HDL-cholesterol levels are actually increased in response to LCAT deficiency
upon Western-type diet feeding (Furbee et al. 2002; Lee et al. 2004). It thus seems
that the diverse effects of LCAT deficiency on atherosclerosis outcome in the
different mouse models cannot be attributed to the HDL deficiency, but are rather
a consequence of the genotype-associated changes in plasma levels of apoB-
containing lipoproteins (Kunnen and Van Eck 2012).
6 Phospholipid Transfer Protein
Transfer of cholesterol esters generated by LCAT to the core of the HDL particles
and the subsequent maturation of the HDL particles require the action of phospho-
lipid transfer protein (PLTP), which supplies phospholipids allowing surface
expansion of the shell of the particles. The phospholipids are liberated during the
lipolysis of triglycerides in the core of apoB-containing lipoproteins by the action of
lipoprotein lipase (Tall et al. 1985). In addition, PLTP facilitates the fusion of
HDL3 particles to enlarged particles (Lusa et al. 1996). During this process lipid-
poor apoA-I particles are released that can act as substrate for ABCA1-mediated
cholesterol efflux from macrophages. In humans, common variants of PLTP have
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been identified that are associated with alterations in serum HDL cholesterol and
the accumulation of small HDL particles (Albers et al. 2012). Furthermore, PLTP
expression and activity is regulated during several diseases, including sepsis,
multiple sclerosis, cancer, and cardiovascular disease (Albers et al. 2012), but it
is largely unknown if the regulation of PLTP is a causative factor or simply a
consequence of the processes underlying the diseases. The generation of PLTP
knockout mice by the group of Alan Tall 15 years ago has greatly contributed to the
general understanding of the role of PLTP in HDL metabolism. PLTP was
inactivated in mice by replacing exon 2 containing the translation initiation
codon, the signal peptide, and the first 16 amino acids of mature PLTP with a
neomycin-resistant gene (Jiang et al. 1999). The plasma transfer activity of the
major phospholipids, including phosphatidylcholine, phosphatidylethanolamine,
phosphatidylinositol, and sphingomyelin into HDL, was completely blocked,
while also the transfer of free cholesterol was impaired in PLTP knockout mice.
Deletion of PLTP in mice led to markedly decreased levels of HDL phospholipids
and cholesterol (65–70 %), illustrating the importance of transfer of surface
phospholipids from apoB-containing lipoproteins by PLTP for maintaining HDL
levels (Jiang et al. 1999). Furthermore, similarly as described for LCAT knockout
mice the decrease in HDL cholesterol coincided with a significant decrease in
plasma apoA-I levels. Hepatocytes isolated from PLTP knockout mice synthesized
normal amounts of apoA-I, albeit with reduced amounts of phosphatidylcholine
(Siggins et al. 2007), indicating that the reduced plasma apoA-I levels were not due
to impaired production. Qin et al. showed by in vivo turnover studies using
autologous HDL that the reduced apoA-I levels are likely the consequence of
increased catabolism of HDL in the PLTP knockout mice (Qin et al. 2000).
On regular chow diet, PLTP-deficient mice absorb less cholesterol in the intes-
tine (Liu et al. 2007), while hepatic phospholipids are increased and triglycerides
are reduced in mice lacking PLTP (Siggins et al. 2007).
Feeding the mice a high saturated fat diet, containing 20 % hydrogenated
coconut oil and 0.15 % cholesterol, led to the accumulation of surface components
of apoB-containing lipoproteins as evidenced by a massive increase in VLDL and
LDL phospholipids and cholesterol in the absence of changes in apoB (Jiang
et al. 1999). Subsequent studies showed that the animals accumulated phospholipid
and free cholesterol-rich lamellar particles containing apoA-IV and apoE (Qin
et al. 2000). The accumulation of the lamellar particles specifically in coconut
oil-fed PLTP knockout mice has been attributed to markedly reduced removal of
these particles via scavenger receptor BI (SR-BI) by parenchymal liver cells
(Kawano et al. 2002) and impaired secretion of biliary cholesterol and phospholipid
(Yeang et al. 2010). Interestingly, these particles did not accumulate in the circula-
tion when the mice were fed regular chow diet or a Western diet, containing 20 %
milk fat and 0.15 % cholesterol (Kawano et al. 2002). In contrast, while feeding a
Western diet, containing milk fat and 0.15 % cholesterol, PLTP deficiency was
associated with an attenuated diet-induced hypercholesterolemia due to twofold
lower concentrations of cholesterol transported by apoB-containing lipoproteins
and HDL. Hepatic and intestinal lipid levels were not affected under these
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conditions, but cholesterol absorption in the intestine was reduced (Shelly
et al. 2008).
Both on chow and while feeding the milk fat Western diet, PLTP knockout mice
display reduced systemic inflammation as evidenced by lower levels of interleukin
6 and reduced expression of intercellular adhesion molecule 1 (ICAM1) and
vascular adhesion molecule 1 (VCAM1) in aorta, indicating that mice lacking
PLTP might have a reduced atherosclerosis susceptibility (Shelly et al. 2008).
To study the effect of PLTP deficiency on atherosclerotic lesion development,
PLTP knockout mice were crossbred with human apoB transgenic mice, apoE
knockout mice, and LDLr knockout mice (Jiang et al. 2001). Both in the apoB
transgenic and the apoE knockout background, PLTP deficiency led, on top of the
reduction in HDL lipids, to substantially lower VLDL lipid levels. Interestingly,
this effect on VLDL lipids was not found in the LDLr knockout background,
indicating the involvement of the LDLr in the lowering of VLDL lipids. In line,
apoB production was reduced in the apoB transgenic and apoE knockout back-
ground, but not in the LDLr knockout background (Jiang et al. 2001). The content
of the antioxidant vitamin E was significantly increased in all three backgrounds in
the absence of PLTP, while autoantibodies to oxidized LDL were largely decreased
(Jiang et al. 2002). HDL isolated from PLTP knockout mice crossbred to both the
apoB transgenic and the LDLr knockout background displayed improved anti-
inflammatory properties and reduced the ability of LDL to induce monocyte
chemotaxis (Yan et al. 2004). After 6 months of feeding apoB transgenic mice
Western diet and after feeding apoE knockout mice chow for 3 months, atheroscle-
rotic lesion size was reduced fivefold in mice lacking PLTP. In contrast, in LDLr
knockout mice PLTP deficiency led to a twofold reduction in atherosclerotic lesion
size after 8 weeks Western diet, whereas no significant effects were observed after
12 weeks Western diet feeding (Jiang et al. 2001). Thus, while PLTP deficiency can
reduce early atherosclerotic lesion development in mice lacking the LDLr, the
pro-atherogenic effects of PLTP should be primarily attributed to its effects on
the production of apoB-containing lipoproteins in mice fed regular chow or a
Western diet. Notably, when apoE knockout mice lacking PLTP were challenged
with a coconut oil-enriched, high fat diet for 7 weeks plasma levels of free
cholesterol were 23 % higher due to the accumulation of the lamellar free choles-
terol and phospholipid-rich particles. Under these conditions no effects on athero-
sclerotic lesion development were found (Yeang et al. 2010).
PLTP is widely distributed with expression in placenta > pancreas > lung >
kidney > heart > liver > skeletal muscle > brain (Day et al. 1994). In addition,
PLTP is found in endothelial cells (Day et al. 1994) and in smooth muscle cell and
macrophage foam cells in atherosclerotic lesions (Desrumaux et al. 2003; Laffitte
et al. 2003; O’Brien et al. 2003). Interestingly, Vikstedt and colleagues showed that
the expression of PLTP is sixfold higher in Kupffer cells, macrophages of the liver
as compared to hepatocytes (Vikstedt et al. 2007). Mice with a hepatocyte-specific
deletion of PLTP were generated by injection of PLTP-flox/flippase animals with
adenovirus-associated virus expressing Cre-recombinase under control of the thy-
roxine binding globulin promoter (Yazdanyar et al. 2013). PLTP activity was
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reduced by approximately 25 % in these animals with a hepatocyte-specific deletion
of PLTP, leading to a 20 % reduction of HDL cholesterol. In addition, non-HDL
cholesterol was 29 % lower due to an impaired production of apoB-containing
lipoproteins (Yazdanyar et al. 2013). Conversely, liver-specific expression of PLTP
in a PLTP knockout background promoted the secretion of apoB-containing
lipoproteins by the liver (Yazdanyar and Jiang 2012). The contribution of macro-
phage PLTP to plasma PLTP activity was determined by bone marrow transplanta-
tion studies in LDLr knockout mice. Selective deletion of PLTP in bone marrow-
derived cells led to a decrease in plasma PLTP activity on chow and Western diet
(Vikstedt et al. 2007). Vikstedt et al. showed that after 9 weeksWestern diet feeding
atherosclerotic lesion size was 29 % smaller in LDLr knockout mice transplanted
with PLTP-deficient bone marrow, which coincided with decreased serum VLDL-
cholesterol and phospholipid levels, while HDL phospholipid and apoA-I were
increased (Vikstedt et al. 2007). In contrast, Valenta et al. also found lower levels of
cholesterol in apoB-containing lipoproteins upon disruption of PLTP in bone
marrow-derived cells of LDLr knockout mice, but surprisingly atherosclerotic
lesion development was increased (Valenta et al. 2006). No effect on atherosclero-
sis was observed upon transplantation of PLTP-deficient bone marrow into LDLr
knockout mice overexpressing human apoA-I (Valenta et al. 2006). The studies by
Valenta et al. suggest that locally in the arterial wall PLTP produced by
macrophages can be anti-atherogenic. A possible explanation is that PLTP produc-
tion by macrophages promotes ABCA1-mediated cholesterol efflux, as evidenced
by decreased efflux to apoA-I from PLTP-deficient macrophages (Lee-Rueckert
et al. 2006). In agreement, macrophages isolated from PLTP knockout mice were
shown to accumulate more cholesterol upon incubation with native or acetylated
LDL (Ogier et al. 2007). Importantly, the higher levels of lipid-poor apoA-I in
LDLr knockout mice overexpressing human apoA-I can overcome the
pro-atherogenic effects of deletion of PLTP in macrophages, probably by
stimulating the cholesterol efflux capacity of the macrophages.
In summary, the effects of PLTP on atherosclerotic lesion development are
determined by a balance between systemic effects influencing the levels of anti-
atherogenic HDL and pro-atherogenic apoB-containing lipoproteins and the anti-
oxidant vitamin E and local effects of PLTP produced by macrophages in the
arterial wall influencing macrophage apoE production and ABCA1-mediated cho-
lesterol efflux.
7 Scavenger Receptor BI
During the final step of the reverse cholesterol transport process, mature HDL
particles deliver their cholesterol load to the liver for subsequent excretion via the
bile. The transmembrane glycoprotein scavenger receptor BI (SR-BI) is considered
to be the sole mediator of selective uptake of cholesterol esters from HDL by
hepatocytes in mice (Out et al. 2004). Several genetic variations at the SR-BI
locus—either translating in an altered SR-BI protein expression or
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functionality—have been associated with a change in plasma HDL-cholesterol
levels (Hsu et al. 2003; West et al. 2009; Vergeer et al. 2011; Brunham
et al. 2011; Chadwick and Sahoo 2012), which highlights the crucial role for
SR-BI in human HDL metabolism. To uncover the role of SR-BI in lipoprotein
metabolism, the group of Monty Krieger developed a mouse model carrying a
targeted mutation in the SR-BI gene that leads to complete absence of functional
SR-BI protein in all tissues (Rigotti et al. 1997). In addition, a strain of SR-BIatt
mice has been generated by the group of Dennis Huszar in which the SR-BI
promoter is mutated, resulting in a lowered protein expression of SR-BI in liver,
testis, and adrenals (Varban et al. 1998). Furthermore, hypomorphic SR-BI knock-
out mice have been constructed that do not suffer from complete SR-BI deficiency,
but show a restricted expression pattern of the protein in liver, kidney, aorta, and
steroidogenic tissues (Huby et al. 2006).
Total body SR-BI knockout mice are characterized by a diet-independent hyper-
cholesterolemia, which can be primarily attributed to a marked rise in plasma
HDL-cholesterol levels (Rigotti et al. 1997; Van Eck et al. 2003, 2008). The
fractional catabolic rate, plasma decay, and subsequent uptake of
HDL-cholesterol esters by the liver are diminished in SR-BI knockout mice (Out
et al. 2004). SR-BIatt mice similarly show a diminished fractional catabolic rate
and hepatic selective uptake of HDL-associated cholesterol, also leading to a higher
steady-state level of HDL cholesterol in the plasma of these mice (Varban
et al. 1998; Ji et al. 1999). In accordance with a role for hepatic SR-BI in the
regulation of plasma HDL-cholesterol levels, both total body and hepatocyte-
specific restriction of SR-BI expression in hypomorphic SR-BI knockout mice is
also associated with an increase in plasma HDL-cholesterol levels (Huby
et al. 2006). Although SR-BI is thought to primarily mediate the uptake
HDL-cholesterol esters, in particular free cholesterol levels are higher in plasma
in the different SR-BI-deficient mice (Van Eck et al. 2003; Huby et al. 2006; El
Bouhassani et al. 2011). The increase in plasma free cholesterol to cholesterol ester
ratio underlies anemia and thrombocytopenia phenotypes in SR-BI knockout mice
(Holm et al. 2002; Meurs et al. 2005; Dole et al. 2008; Korporaal et al. 2011) and
can be attributed to a reduction in the LCAT activity (El Bouhassani et al. 2011). As
judged by the unchanged plasma apoA-I levels in total body SR-BI knockout mice,
only the size and cholesterol content but not the absolute number of HDL particles
is increased in response to SR-BI deficiency (Rigotti et al. 1997). The enlarged
HDL particles observed in plasma of SR-BI knockout mice are highly enriched in
apoE. In contrast, apoA-II cannot be detected in the HDL fraction of SR-BI-
deficient mice, which suggests a generally altered apolipoprotein composition
(Rigotti et al. 1997). In line with the notion that SR-BI facilitates HDL-mediated
reverse cholesterol transport, the recovery of radiolabeled cholesterol in feces upon
injection of either peritoneal or J774 macrophages is lower in SR-BI knockout mice
as compared to their wild-type littermate controls, despite an increased appearance
of radioactivity in the plasma (HDL) compartment (Zhang et al. 2005a; Zhao
et al. 2011).
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SR-BI knockout mice also display a significant increase in non-HDL-cholesterol
levels (Rigotti et al. 1997; Van Eck et al. 2003, 2008). Hepatic VLDL secretion and
LPL-mediated lipolysis rates are not affected by SR-BI deficiency (Van Eck
et al. 2008). SR-BI has been shown to be directly involved in the selective uptake
of cholesterol esters from LDL and VLDL particles by hepatocytes (Rhainds
et al. 2003; Van Eck et al. 2008). It can therefore be anticipated that the increase
in the level of cholesterol associated with apoB-containing lipoproteins in SR-BI
knockout mice is directly resulting from a diminished clearance by the liver.
Two variations in the SR-BI gene have been linked to changes in fertility in
humans (Yates et al. 2011). Without dietary addition of the lipid-lowering drug
probucol, SR-BI knockout female mice are virtually sterile, with a ~90 % reduction
in fertility and pup yield as compared to wild-type controls (Miettinen et al. 2001).
The development of SR-BI knockout embryos is impaired in ex vivo cultures
(Trigatti et al. 1999). Furthermore, developmental abnormalities are also observed
in SR-BI knockout embryos in vivo (Santander et al. 2013). Although steroidogenic
tissues, i.e., ovaries and adrenals, from SR-BI knockout mice exhibit an apparent
decrease in their cholesterol ester stores (Rigotti et al. 1997; Trigatti et al. 1999),
levels of the steroid hormone progesterone as well as the number of oocytes and
cyclic activity are unaffected by murine SR-BI deficiency (Trigatti et al. 1999). The
lack of pups generated from SR-BI-deficient breedings can thus rather be attributed
to embryonic defects than to infertility of the mothers.
Human carriers of functional mutations in the SR-BI gene exhibit a decrease in
their adrenal steroidogenesis rate (Vergeer et al. 2011). Similarly, depletion of
adrenocortical cholesterol stores due to SR-BI deficiency translates into a signifi-
cant change of the adrenal steroid function in mice. Basal glucocorticoid levels in
plasma are similar between SR-BI knockout and wild-type mice (Hoekstra
et al. 2008). However, total body SR-BI deficiency is associated with primary
glucocorticoid insufficiency. Total body SR-BI knockout mice display increased
plasma ACTH levels and are unable to increase their adrenal glucocorticoid output
in response to established steroidogenic triggers (Cai et al. 2008; Hoekstra
et al. 2008, 2009). It appears that SR-BI-mediated uptake of HDL-cholesterol esters
by the adrenals is necessary for a proper steroid output, since the glucocorticoid
function is also impaired in adrenocortical cell-specific SR-BI knockout mice
(Hoekstra et al. 2013b). In further support, hepatocyte-specific SR-BI deficiency
does not lower adrenal cholesterol levels or impair the adrenal corticosterone
response to fasting (El Bouhassani et al. 2011).
No atherosclerotic lesion development is normally observed in normolipidemic
wild-type mice upon feeding a regular chow diet or a high cholesterol high fat
Western-type diet that does not contain cholic acid. No atherosclerotic plaques can
also be detected in the aortic root of chow-fed SR-BI knockout mice (Zhao
et al. 2011). In contrast, SR-BI knockout mice with increased HDL-cholesterol
levels do readily develop macrophage-rich fatty streak lesions after 20 weeks of
Western-type diet feeding (Van Eck et al. 2003). SR-BI knockout mice display an
increase in non-HDL cholesterol under these feeding conditions (Van Eck
et al. 2003). However, the measured levels of apoB-containing lipoproteins upon
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Western-type diet feeding are still considered to be too low to stimulate the
formation of atherosclerotic lesions. This suggests that other SR-BI-related
mechanisms may underlie the susceptibility for Western-type diet-induced athero-
genesis in SR-BI knockout mice. Follow-up studies in liver-specific hypomorphic
SR-BI knockout mice have indicated that the SR-BI-mediated atheroprotection
originates from both hepatic and peripheral cell sources (Huby et al. 2006; El
Bouhassani et al. 2011). A similarly increased susceptibility for atherosclerosis
upon ablation of total body SR-BI function has been noted in response to feeding a
cholic acid-containing atherogenic diet (Zhang et al. 2005b). In accordance with a
role for SR-BI in the clearance of apoB-containing lipoproteins, high fat diet-fed
SR-BIatt x LDLr knockout mice exhibit higher plasma LDL-cholesterol levels and
an increased extent of atherosclerosis as compared to LDLr knockout controls
(Huszar et al. 2000). In contrast, total body SR-BI deficiency in high fat diet-fed
LDLr knockout mice is associated with lower VLDL/LDL levels, but a similarly
enhanced formation of atherosclerotic lesions in the context of a higher plasma
HDL-cholesterol concentration (Covey et al. 2003). Loss of total body SR-BI
function in chow diet-fed hyperlipidemic apoE knockout mice is associated with
severe cardiac dysfunction, i.e., a reduced contractility and ejection fraction, and
occlusion of the coronary arteries, leading to premature death of these animals at
the age of 6–8 weeks (Braun et al. 2002). Occlusive coronary atherosclerosis and an
increased extent of atherosclerosis in the aortic root are also seen upon genetic
deletion of SR-BI in atherogenic diet-fed hypomorphic APOER61h/h mice (Zhang
et al. 2005b). An optimal total body SR-BI function thus protects against athero-
sclerosis and myocardial infarction, through (1) its role in hepatic uptake of
lipoprotein-derived cholesterol and (2) via its action extrahepatic/peripheral cells.
In rodents, high expression of SR-BI is not only found in liver and steroidogenic
tissues (Acton et al. 1996), but also in tissue macrophages such as liver Kupffer
cells (Fluiter et al. 1998; Malerød et al. 2002; Hoekstra et al. 2003), which suggests
that SR-BI can also contribute to macrophage cholesterol homeostasis locally
within atherosclerotic lesions. Studies using isolated SR-BI-deficient peritoneal
macrophages have suggested that SR-BI may facilitate cholesterol efflux to mature
HDL (Van Eck et al. 2004). However, macrophage SR-BI does not contribute to
reverse cholesterol in vivo, based upon radiolabeled cholesterol recovery studies
(Wang et al. 2007). Bone marrow transplantation studies have been executed to
delineate the specific role of macrophage SR-BI in the protection against athero-
sclerosis. Transplantation of SR-BI knockout bone marrow into LDLr knockout
mice stimulates atherogenesis without altering plasma lipoprotein cholesterol levels
(Covey et al. 2003; Van Eck et al. 2004). Inactivation of macrophage SR-BI also
promotes the development of atherosclerotic plaques in the context of unchanged
lipid levels in apoE knockout mice (Zhang et al. 2003). In addition, the cardiac
hypertrophy and dysfunction and coronary atherosclerosis development are
attenuated upon restoration of macrophage SR-BI function in apoE x SR-BI double
knockout mice (Pei et al. 2013). Strikingly, in marked contrast to the findings from
hyperlipidemic mice, disruption of macrophage SR-BI expression in
normolipidemic C57BL/6 mice results in a lower susceptibility for atherosclerosis
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upon feeding a cholic acid-containing atherogenic diet (Van Eck et al. 2004).
C57Bl/6 mice fed a cholic acid-containing atherogenic diet develop small initial
atherosclerotic lesions, suggesting that SR-BI might be pro-atherogenic in this early
stage of lesion development. In line, early atherosclerotic lesion development in
LDLr knockout mice challenged with Western diet for only 4 weeks was reduced
upon disruption of SR-BI in bone marrow-derived cells. These combined studies
suggest that macrophage SR-BI plays a dual role in foam cell formation and
atherogenesis, which may be dependent on the stage of atherosclerotic lesion
development.
8 Insights from Intercrossing of the Different Knockout Mice
Since some of the aforementioned proteins execute both different and overlapping
functions in the formation of HDL particles and reverse cholesterol transport, it is
conceivable that they may act synergistically and/or be able to compensate for each
other’s loss. To uncover interactions between specific gene products several double
knockout mice have been generated via intercrossing. In line with a differential role
in HDL formation and maturation, studies in mice lacking both ABCA1 and LCAT
function have suggested that these two proteins act synergistically. Hepatic choles-
terol accumulation is higher, while peripheral tissue cholesterol levels are lower in
ABCA1 x LCAT double knockout mice as compared to the respective single
knockout mice, despite an even higher HDL fractional catabolic rate (Hossain
et al. 2009). In parallel, probucol-induced inhibition of ABCA1 function further
lowers adrenal cholesterol levels in LCAT knockout mice (Tomimoto et al. 2001).
The ABCA1-mediated formation of HDL particles rather than the SR-BI-mediated
cholesterol uptake is the driving force in the maintenance of plasma
HDL-cholesterol levels, as HDL-cholesterol levels in ABCA1 x SR-BI double
knockout mice are still close to zero (Zhao et al. 2011). In contrast, ablation of
either ABCA1 or SR-BI function is equally effective in lowering the rate of in vivo
macrophage reverse cholesterol transport (Zhao et al. 2011). The mild pulmonary
lipidosis phenotype of ABCA1 knockout mice is severely aggravated in response to
deletion of SR-BI function, which suggests that macrophage SR-BI is able to
partially compensate for the inability of ABCA1 to mediate cholesterol efflux
(Zhao et al. 2011). In accordance, specific disruption of both ABCA1 and SR-BI
in bone marrow-derived cells of LDLr knockout mice leads to an added increase in
(tissue) macrophage foam cell formation and Western-type diet-induced athero-
sclerotic lesion development, in the context of lower plasma cholesterol levels,
when compared to both single knockout bone marrow transplanted controls (Zhao
et al. 2010). Importantly, ABCG1 seems to play a more essential role in the
compensatory response to macrophage ABCA1 deficiency. Mass efflux of choles-
terol from macrophages to both apoA-I and HDL is virtually absent as a result of
combined deletion of ABCA1 and ABCG1 (Out et al. 2008a). Already on a chow
diet ABCA1 x ABCG1 double knockout mice display marked accumulation of
cholesterol not only within the lungs (reminiscent of the ABCG1 knockout
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phenotype), but also in primary and secondary lymphoid organs and macrophage-
rich areas of the liver and intestine (Out et al. 2008a). Furthermore, the double
deletion exacerbates high fat diet-induced lymphocytosis (Yvan-Charvet
et al. 2008). Transplantation of bone marrow from ABCA1 x ABCG1 double
knockout mice into LDLr knockout mice is associated with resistance to
Western-type diet-induced hyperlipidemia (Out et al. 2008b). However, despite
the rather low plasma cholesterol levels under Western-type diet feeding
conditions, ABCA1 x ABCG1 double knockout bone marrow recipient mice
show significant plaque development and exhibit distinct lipid deposition in
macrophage-rich tissues (Out et al. 2008b). This highlights the necessity for these
transporters to overcome macrophage foam cell formation and atherosclerosis.
Subsequent bone marrow transplantations into mice with a heterozygous mutation
in the LDLr gene (LDLr+/) have validated the increased susceptibility to macro-
phage cholesterol accumulation and atherosclerosis in response to the combined
deficiency in macrophage ABCA1 and ABCG1 upon challenge with a cholate-
containing diet (Yvan-Charvet et al. 2007). Furthermore, these studies have
suggested that the combined deficiency of these ABC transporters in bone marrow
also impacts on the inflammatory function and susceptibility to apoptosis of
macrophages as well as the cyclic activity of hematopoietic stem cells (Yvan-
Charvet et al. 2008, 2010a).
9 Conclusions from the Gene Knockout Mouse Studies
Generation of the different knockout mice has significantly contributed to our
understanding of HDL’s metabolism and function (see Fig. 1 for overview). It
has become clear that the initial generation and maturation of HDL particles as well
as the selective uptake of its cholesterol by the liver are important parameters in the
life cycle of HDL. In line with the proposed atheroprotective function of HDL,
murine HDL deficiency consistently predisposes to the development of atheroscle-
rotic lesions. However, it should be noted that many of the detrimental atheroscle-
rosis effects observed in response to HDL deficiency in mice cannot be solely
attributed to the low HDL levels per se, as the low HDL levels are in most models
paralleled by changes in non-HDL-cholesterol levels. Although in the human
setting, low HDL-cholesterol levels predict increased cardiovascular risk at all
plasma non-HDL-cholesterol levels, the mouse data firmly establish that HDL
and non-HDL metabolism are heavily intertwined.
Based upon the bone marrow transplantation studies in hyperlipidemic mice, it
appears that the cholesterol efflux function of HDL is of critical importance to
overcome foam cell formation and the development of atherosclerotic lesions. We
therefore consider it therapeutically highly relevant to increase the expression
and/or activity of the cholesterol transporters in macrophages. In this regard, special
focus should be given to macrophage ABCA1 as this transporter seems to be the
driving force in the atheroprotection.
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Although HDL is predominantly studied for its atheroprotective action, it can be
appreciated that the mouse data suggest an essential role for HDL as cholesterol
donor for steroidogenic tissues, including the adrenals and ovaries. Furthermore, it
appears that a relevant interaction exists between HDL-mediated cellular choles-
terol efflux and the susceptibility to inflammation, which (1) provides strong
support for the novel concept that inflammation and metabolism are intertwining
biological processes and (2) identifies the efflux function of HDL as putative
therapeutic target also in other inflammatory diseases than atherosclerosis, includ-
ing sepsis and diabetes.
10 Cholesterol Ester Transfer Protein Transgenic Mice
Despite the fact that a great deal regarding the function of specific gene products
has been learned from the murine transgenic studies it should be acknowledged that
one should take care when directly translating the data to the human situation.
Humans, in contrast to mice, naturally express cholesterol ester transfer protein
(CETP) that plays a major role in total body cholesterol homeostasis as it is able to
exchange cholesterol esters and triglycerides between cholesterol-rich HDL and
ApoA-I knockout
- Plasma HDL-C ↓↓↓
- Adrenal cholesterol ↓;  adrenal funcon ↓
- Ovarian cholesterol ↓;  female ferlity =
- Atherosclerosis  ↑ (LDLr  KO on chow); plasma VLDL-C ↑ 
- Atherosclerosis  =  (LDLr KO on Western diet); plasma VLDL-C ↓
- Development of skin lesions containing lipid-ﬁlled macrophages
- Cholesterol in B and T cells of lymph nodes ↑
ABCG1 knockout
- Plasma HDL-C =
- Adrenal funcon ?
- Female ferlity =
- Pulmonary lipidosis
- Inial atherosclerosis↑
- Advanced atherosclerosis ↓
- Similar eﬀects in general KO’s
and bone marrow deleon
ABCA1 knockout
- Plasma HDL-C ↓↓↓
- Adrenal cortex cholesterol esters  ↑
- Female ferlity  ↓;  steroid hormones ↓ ;  placenta malformaons
- Atherosclerosis =;  plasma VLDL-C  ↓
- Bone marrow deleon: atherosclerosis ↑,  blood leukocytes  ↑
- Macrophage/Neutrophil deleon: atherosclerosis  =
- Liver deleon:  atherosclerosis  =  (LDLr KO), atherosclerosis  ↑ (apoE KO)
LCAT knockout
- Plasma HDL-C ↓↓↓ 
- Adrenal cholesterol ↓;  adrenal funcon ↓ 
- Female ferlity  =
- Plasma TG ↑ and VLDL-C ↑
- Atherosclerosis  =↓↑ (depending on the
genec background, diet and eﬀects on
plasma VLDL-C)
PLTP knockout
- Plasma HDL-C ↓↓
- Adrenal funcon ?
- Female ferlity  =
- PL and FC-rich lamellar parcles  ↑ (saturated fat-rich diet)
- Atherosclerosis ↓=  (depending on the genec background, diet
and eﬀects on plasma VLDL-C)
- Bone marrow deleon:  atherosclerosis ↓↑;  plasma VLDL-C ↓
SR-BI knockout
- Plasma HDL-C ↑↑
- Plasma VLDL-C ↑
- Adrenal cholesterol ↓;  adrenal funcon ↓ 
- Female ferlity ↓; abnormal embryo development
- Atherosclerosis  ↑
- Severe cardiac dysfuncon and premature death in apoE KO’s
- Bone marrow deleon: inial lesions ↓,  advanced lesions  ↑
Fig. 1 Major phenotypic changes in mouse models of disturbed HDLmetabolism. An overview is
given of the effects of deletion of apolipoprotein A-I (apoA-I), the ABC transporters A1 (ABCA1)
and G1 (ABCG1), lecithin-cholesterol acyltransferase (LCAT), phospholipid transfer protein
(PLTP), and scavenger receptor BI (SR-BI) for HDL’s metabolism, adrenal function, female
fertility, and its protection against atherosclerosis in mice. ¼ no effect, # decreased, " increased,
C cholesterol, PL phospholipids, TG triglycerides, KO knockout
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triglyceride-rich VLDL/LDL particles. In agreement with a major role for CETP in
the modulation of plasma HDL-cholesterol levels, genetic CETP deficiency is
associated with marked hyperalphalipoproteinemia, i.e., relatively high
HDL-cholesterol levels, in humans (Rhyne et al. 2006; Calabresi et al. 2009). To
overcome this apparent discrepancy between mice and humans in studies dealing
with lipoprotein metabolism, the group of Alan Tall generated a mouse line
(NFR-CETP) expressing the human CETP transgene under the control of its natural
flanking regulatory elements (Jiang et al. 1992). Initial cloning studies (Drayna
et al. 1987) indicated that CETP is primarily derived from liver, small intestine,
adrenals, and spleen in humans. In accordance, relatively high CETP mRNA levels
are found in liver, spleen, and small intestine of human NFR-CETP transgenic mice
(Jiang et al. 1992). Of note, the Tall group also generated a transgenic mouse line
expressing CETP under control of the methallothionein-I (MT) gene (Jiang
et al. 1992). In MT-CETP transgenic mice, additional high expression of CETP
can be detected in kidney, adipose tissue, and heart. Importantly, the expression of
CETP in MT-CETP transgenic is not responsive to high cholesterol/high fat diet
feeding, which contrasts the findings from NFR-CETP transgenic mice (Jiang
et al. 1992) and species naturally expressing CETP, i.e., monkeys and rabbits
(Quinet et al. 1990; Pape et al. 1991). Given the apparent limitations of
MT-CETP transgenic mice, in our opinion the NFR-CETP mouse model should
preferentially be used in studies aimed at translation to the human situation.
Therefore, findings from NFR-CETP transgenic mice will only be reviewed in
the next part.
Chow-fed CETP transgenic mice exhibit a ~15 % lower plasma total cholesterol
level as compared to non-transgenic controls (Masucci-Magoulas et al. 1996;
Harada et al. 2007). In contrast, plasma triglyceride levels are marginally increased
in CETP carrying mice upon feeding chow diet (Zhou et al. 2006; Harada
et al. 2007) due to a slightly diminished clearance of triglyceride-rich lipoproteins
(Salerno et al. 2009). The decrease in total cholesterol in CETP transgenic mice can
primarily be attributed to lower levels of cholesterol associated with HDL (Zhou
et al. 2006). The fractional catabolic rate and uptake of HDL-cholesterol esters by
the liver, adrenals, and adipose tissue are increased in CETP transgenic mice, which
is associated with an increase in hepatic cholesterol stores (Harada et al. 2007). As a
result, CETP transgenic mice exhibit a rise in the plasma total cholesterol over
HDL-cholesterol ratio (Clee et al. 1997). The decrease in HDL-cholesterol levels
cannot be attributed to a change in LCAT levels. Intriguingly, the presence of CETP
actually enhances the saturation level of the LCAT-mediated cholesterol esterifica-
tion reaction (Oliveira et al. 1997). This suggests that CETP generates particles that
can serve as optimal substrates for LCAT.
Despite the marked increase in plasma HDL-cholesterol levels associated with
complete CETP deficiency, variable effects on atherosclerosis and cardiovascular
disease risk in response to genetic variations in the CETP gene have been noted in
the human setting (Zhong et al. 1996; Agerholm-Larsen et al. 2000; Curb
et al. 2004; Zheng et al. 2004; Rhyne et al. 2006). To provide clear insight into
the contribution of CETP to atherosclerotic lesion development, NFR-CETP
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transgenic mice have been bred onto several different atherosclerosis-susceptible
mouse backgrounds. CETP expression in heterozygous LDLr knockout mice on a
cholic acid-containing atherogenic diet does not significantly alter plasma HDL- or
non-HDL-cholesterol levels. As a result, CETP does not impact on the susceptibil-
ity to atherosclerosis in heterozygous LDLr knockout mice (Casquero et al. 2006).
In contrast, CETP executes a clear pro-atherogenic effect in hyperlipidemic apoE
knockout and homozygous LDLr knockout mice (Plump et al. 1999). CETP lowers
plasma HDL-cholesterol levels in chow-fed apoE knockout mice without changing
levels of cholesterol associated with non-HDL particles. In addition, triglyceride
levels are increased in the plasma of CETP-expressing apoE knockout mice. CETP
expression does not alter plasma HDL-cholesterol levels in LDLr knockout mice
challenged with a Western-type high fat/high cholesterol diet. However, levels of
cholesterol associated with pro-atherogenic apoB-containing lipoproteins are mark-
edly increased in response to CETP expression in LDLr knockout mice. It thus
appears that the increased atherosclerotic lesion development in apoE and LDLr
knockout mice upon CETP expression can be directly related to an increased
atherogenic index of the plasma compartment (higher non-HDL/HDL ratio) in
both types of hyperlipidemic mice. In further support, a marked increase in plasma
non-HDL-cholesterol levels and atherosclerotic lesion development—in the con-
text of a marginal but significant decrease in HDL-cholesterol levels—was noted
when we expressed CETP only in bone marrow-derived cells of LDLr knockout
mice through bone marrow transplantation (Van Eck et al. 2007).
A clear drawback of using LDLr and apoE knockout mice for studies regarding
lipoprotein metabolism is that they do not exhibit a normal clearance of apoE-
containing VLDL/LDL particles. To determine the effect of CETP expression on
lipoprotein metabolism and atherosclerosis development in a more relevant
“humanized” setting, CETP transgenic mice have also been crossbred with
hyperlipidemic apoE*3-Leiden mice. Transgenic apoE*3-Leiden mice express a
mutation of the human apoE3 gene resulting in a slightly attenuated clearance of
apoB-containing particles via the LDLr pathway (van den Maagdenberg
et al. 1993). As a result, these mice (1) exhibit a lipoprotein cholesterol distribution
profile that is highly similar to that found in humans (van den Maagdenberg
et al. 1993; van Vlijmen et al. 1994), (2) are susceptible to atherosclerotic lesion
development when fed a high fat/high cholesterol Western-type diet devoid of
cholic acid (van Vlijmen et al. 1994), and (3) show a similar plasma lipid response
as human subjects to several drug interventions (van der Hoogt et al. 2007; de Haan
et al. 2008a; van der Hoorn et al. 2008). ApoE*3-Leiden x CETP double transgenic
mice as compared to apoE*3-Leiden controls display a significant increase in
plasma total cholesterol levels on both chow and under Western-type diet feeding
conditions (Westerterp et al. 2006). Under these dietary conditions, VLDL-
cholesterol levels are increased twofold, while HDL-cholesterol levels as well as
plasma apoA-I levels are 25 % lower in apoE*3-Leiden x CETP transgenic mice
(Westerterp et al. 2006). Importantly, apoE*3-Leiden x CETP transgenic mice
exhibit increased atherosclerotic lesion development in the aortic root as compared
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to apoE*3-Leiden controls (Westerterp et al. 2006). Based upon these combined
findings, CETP should clearly be considered a pro-atherogenic protein moiety.
In the last decade, therapeutic strategies have focused on inhibiting CETP
activity through the use of a variety of CETP-binding drugs, i.e., torcetrapib, that
form an inactive complex between CETP and HDL. Studies in apoE*3-Leiden x
CETP transgenic mice have suggested that the HDL increase associated with
torcetrapib treatment does not add to the beneficial impact of statin-induced lipid-
lowering on atherosclerosis (de Haan et al. 2008b). Importantly, the ILLUMINATE
and dal-OUTCOMES trials also failed to show the beneficial effect of CETP
inhibition in statin-treated cardiovascular disease patients (Barter et al. 2007;
Schwartz et al. 2012). Combination treatment with torcetrapib and statin increases
the macrophage content in atherosclerotic lesions in apoE*3-Leiden x CETP
transgenic mice as compared to statin treatment alone (de Haan et al. 2008b). A
higher lesional macrophage content is generally associated with an increased
susceptibility for plaque rupture and future cardiovascular events in the human
situation (Redgrave et al. 2006; Marnane et al. 2014). An effect of CETP inhibition
on plaque stability may therefore possibly have contributed to the negative outcome
of the aforementioned torcetrapib and dalcetrapib trials.
Concluding Remark
The use of dedicated knockout and transgenic mouse models has significantly
increased our knowledge on the different functions and metabolism of HDL.
However, as evident from the recent failures of the CETP inhibition-based
clinical trials, more research is clearly needed to better understand how we can
use HDL as target in the treatment of patients at risk of cardiovascular disease
and other immune-related disorders. The generation of “humanized” mouse
models such as the apoE*3-Leiden x CETP transgenic mice will hopefully aid
in the development of novel therapeutic approaches beneficially impacting on
HDL functionality and atherosclerosis outcome also in the clinical setting.
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